Neoleukin Therapeutics (Neoleukin Therapeutics) Cash Conversion Cycle : 0.00 (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Neoleukin Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2023 was 0.
Neoleukin Therapeutics's Days Inventory for the three months ended in Sep. 2023 was .
Neoleukin Therapeutics's Days Payable for the three months ended in Sep. 2023 was .
Therefore, Neoleukin Therapeutics's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2023 was 0.00.

Neoleukin Therapeutics Cash Conversion Cycle Historical Data

The historical data trend for Neoleukin Therapeutics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics Cash Conversion Cycle Chart

Neoleukin Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash Conversion Cycle

Get a 7-Day Free Trial

7.13

Neoleukin Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash Conversion Cycle	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Neoleukin Therapeutics's Cash Conversion Cycle

For the Biotechnology subindustry, Neoleukin Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neoleukin Therapeutics's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Neoleukin Therapeutics's Cash Conversion Cycle falls into.

Neoleukin Therapeutics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Neoleukin Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+		-
	=	0.00

Neoleukin Therapeutics's Cash Conversion Cycle for the quarter that ended in Sep. 2023 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+		-
	=	0.00

Neoleukin Therapeutics (NAS:NLTX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Neoleukin Therapeutics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102

Website

https://www.neoleukin.com

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Executives

Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith	officer: Principal Accounting Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel	officer: Chief Medical Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle	director	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener	officer: General Counsel, SVP Legal	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar	director	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman	director, officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey	officer: Senior Vice President	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho	officer: Chief Financial Officer	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance	officer: General Counsel	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle	director	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080